Integration of genomic aberrations to predict clinical outcomes for patients with gastroesophageal adenocarcinoma receiving neoadjuvant chemotherapy.

ESMO Gastrointest Oncol · 2024 · PMC12836727 · PMID 41648744

Europe PMC DOI

hedged sentence

0.0559

closest p · 1.1× alpha

0.0559

boldest claim

The sentences

only marginally significantP = 0.0559so close (0.05 < p ≤ 0.1)

However, the choice of physician-directed neoadjuvant therapy was only marginally significant ( P = 0.0559) after adjusting for these factors.

also in 5,085 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.